New combo therapy aims to control prostate cancer spread without lifelong drugs
NCT ID NCT03007732
First seen Jan 06, 2026 · Last updated May 13, 2026 · Updated 23 times
Summary
This study tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to targeted radiation could help control prostate cancer that has spread to a few places in the body. Twenty-three men with newly diagnosed, hormone-sensitive prostate cancer took part. The goal was to see if this approach could keep PSA levels low and delay the need for long-term hormone therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.